ANI Pharmaceuticals, Inc. (ANIP)
| Market Cap | 1.71B |
| Revenue (ttm) | 826.88M |
| Net Income (ttm) | 34.15M |
| Shares Out | 20.90M |
| EPS (ttm) | 1.67 |
| PE Ratio | 48.82 |
| Forward PE | 10.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 519,627 |
| Open | 82.53 |
| Previous Close | 82.74 |
| Day's Range | 80.57 - 83.14 |
| 52-Week Range | 52.50 - 99.50 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 99.29 (+21.43%) |
| Earnings Date | Nov 7, 2025 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group pu... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price target is $99.29, which is an increase of 21.43% from the latest price.
News
ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients Expert retina and uveitis specialists ...
ANI Pharmaceuticals Announces Board Transition
Patrick D. Walsh steps down as Chairman and will complete his current term as Board member Thomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board
ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir...
ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir...
ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. ( ANIP) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Nikhil Lalwani - President, CEO & Director Christopher Mutz - Senior Vp & Head of Rare Diseas...
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adjus...
ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates
In my opinion, ANI Pharmaceuticals should beat earnings and revenue estimates for the 13th consecutive quarter. Purified Cortrophin sales should lead the way. ANIP should announce approval and marketi...
ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results ...
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings
ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Nikhil Lalwani - President, CEO & Director Conferenc...
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along w...
ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - Preside...
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended ...
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial res...
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will ho...
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress The Use of Pu...
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 J...
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare t...
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief F...
ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Directo...
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended Ma...
ANI Pharmaceuticals: A Short-Term Buying Opportunity
ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new f...
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model
Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE...